Clinical trial / 2019
One year of dietary milled flaxseed did not significantly alter cardiac arrhythmias or claudication distances compared to placebo in PAD patients.
In the double-blinded randomized controlled FLAX-PAD trial, PAD patients consumed a diet supplemented with either 30 g of milled flaxseed or placebo daily for 1 year. At baseline, cardiac arrhythmias were present in 48% of the flaxseed group and 32% of the placebo group. After 1 year, cardiac arrhythmias decreased by 2% in the flaxseed group and increased by 12% in the placebo group, which was not statistically significant (P > 0.05). Electrocardiographic variables did not change in either group, and improvements in initial and absolute claudication distances did not show a statistically significant intergroup difference.
- Study type
- Double-blind randomized controlled trial
- Who was studied
- Patients with peripheral artery disease (PAD)
- What was measured
- Prevalence of cardiac arrhythmias and exercise capacity (claudication distance)
THE PAPER
The effects of dietary flaxseed on cardiac arrhythmias and claudication in patients with peripheral arterial disease 1.
Rodriguez-Leyva D, Rodriguez-Portelles A, Weighell W, Guzman R, Maddaford TG, Pierce GN. Can J Physiol Pharmacol, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.